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Abstract. Neuromyelitis optica (NMO) is a refractory autoimmune inflammatory disease of the central nervous system
without an effective cure. Autologous bone marrow‑derived
mesenchymal stem cells (BM‑MSCs) are considered to be
promising therapeutic agents for this disease due to their
potential regenerative, immune regulatory and neurotrophic
effects. However, little is known about the cytological features
of BM‑MSCs from patients with NMO, which may influence
any therapeutic effects. The present study aimed to compare
the proliferation, differentiation and senescence of BM‑MSCs
from patients with NMO with that of age‑ and sex‑matched
healthy subjects. It was revealed that there were no significant
differences in terms of cell morphology or differentiation
capacities in the BM‑MSCs from the patients with NMO.
However, in comparison with healthy controls, BM‑MSCs
derived from the Patients with NMO exhibited a decreased
proliferation rate, in addition to a decreased expression of
several cell cycle‑promoting and proliferation‑associated
genes. Furthermore, the cell death rate increased in BM‑MSCs
from patients under normal culture conditions and an assessment of the gene expression profile further confirmed that the
BM‑MSCs from patients with NMO were more vulnerable to
senescence. Platelet‑derived growth factor (PDGF), as a major
mitotic stimulatory factor for MSCs and a potent therapeutic
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cytokine in demyelinating disease, was able to overcome the
decreased proliferation rate and increased senescence defects
in BM‑MSCs from the patients with NMO. Taken together,
the results from the present study have enabled the proposition
of the possibility of combining the application of autologous
BM‑MSCs and PDGF for refractory and severe patients with
NMO in order to elicit improved therapeutic effects, or, at the
least, to include PDGF as a necessary and standard growth
factor in the current in vitro formula for the culture of NMO
patient‑derived BM‑MSCs.
Introduction
Neuromyelitis optica (NMO) is a severely disabling inflammatory disease of the central nervous system that predominantly
affects the optic nerves and the spinal cord (1). The prevalence
of NMO worldwide ranges from 0.5‑4.4 cases per 100,000 (2,3)
and the mortality rate directly associated with NMO attacks
ranges from 7 to 30%, predominantly attributable to neurogenic
respiratory failure (4‑6). Most of the treatments for acute attacks
and NMO relapses are targeted to controlling the symptoms,
although large‑scale randomized trials have been too scarce
to allow optimization of the treatment strategies for NMO (7).
Furthermore, immune modulatory and anti‑inflammatory
agents have not been demonstrated to influence the course of
NMO progression and therefore are not suitable for curing
chronic neurological disability. Therefore, novel treatment
modalities to alleviate the disability resulting from NMO have
evoked considerable interest. Much attention has been focused
on restorative therapy, particularly the use of stem cells.
Mesenchymal stem cells (MSCs) are adult non‑hematopoietic pluripotent cells with a high capacity to be induced to
differentiate into other cell lines, including adipocytes, chondrocytes and stromal cells (8). Certain characteristics make
MSCs attractive as therapeutic candidates, including innate
pluripotency, the capacity to facilitate the repair of lesions
through multiple avenues in immune regulation, angiogenesis
and neurogenesis, and their immune privileged status (9). MSCs
may be isolated from various sources, including bone marrow,
adipose tissue (10), umbilical cord (11) and peripheral blood,
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among which the major and most frequently studied source is
the bone marrow. Furthermore, a growing body of pre‑clinical
studies has consistently demonstrated that bone marrow‑derived
MSCs (BM‑MSCs) are capable of safely ameliorating clinical
outcomes of certain neurological degenerative diseases,
including stroke (12) and multiple sclerosis (13,14).
A recent paper published by the authors' laboratory revealed
that the transplantation of autologous BM‑MSCs exerted positive effects in the treatment of NMO (15). However, little is
known about the cytological features of BM‑MSCs from
patients with NMO. In the present study, a comprehensive
comparison of the cytological features of BM‑MSCs from
patients with NMO and healthy subjects was conducted.
The results obtained will provide a general understanding of
BM‑MSCs derived from patients with NMO and may assist
in the optimization of culture and cell proliferation protocols,
thereby leading to improved MSC transplantation results.

Table I. Phenotype characteristics of bone marrow‑mesenchymal stem cells.
Surface
marker

Patients with
NMO (%)

Healthy
control (%)

P‑value

CD29
98.35
99.01
NS
CD34	‑	‑	‑
CD44
96.27
95.98
NS
CD45	‑	‑	‑
CD73
99.15
98.79
NS
CD90
95.30
96.12
NS
CD105
92.28
93.19
NS
CD166
94.25
95.42
NS
CD, cluster of differentiation; NS, not significant; NMO, neuromyelitis optica.

Materials and methods
Patients. Informed consent was obtained from all participants
in the present study and the study was approved by the Tianjin
Medical University General Hospital Institutional Review Board
and Ethics Committee (Tianjin, China). Patients with NMO
were recruited between January 2016 and December 2017 from
Tianjin Medical University General Hospital. The five patients
(all female; patient characteristics are presented in Table SI) were
enrolled on the basis of the following criteria: i) They conformed
with the diagnostic criteria proposed by Wingerchuk et al (3)
in 2007; ii) exclusion criteria included a history of diabetes,
cardio‑ or cerebrovascular diseases and inflammatory, and autoimmune diseases other than NMO; iii) none of the patients had
received corticosteroid or other immunosuppressant therapy
within the last 4 weeks; and iv) all patients exhibited no other
autoimmune diseases and all patients with NMO were monitored over a one year period (detailed information are described
in Table SI). A total of five age‑matched healthy female volunteers were enrolled as health controls.
Isolation and identification of BM‑MSCs. Aliquots of 5‑10 ml
adult donor bone marrow aspirates were provided by the
Department of Hematology of Tianjin Medical University
General Hospital. Bone marrow‑derived mononuclear cells
(BM‑MNCs) were isolated and cultured in Gibco® Dulbecco's
Modified Eagle Medium/Nutrient Mixture F‑12 (D‑MEM/F‑12
medium; Thermo Fisher Scientific, Inc., Waltham, MA, USA)
supplemented with 10% fetal bovine serum (FBS; Hyclone,
Chicago, IL, USA), 100 U/ml penicillin/streptomycin, 2 mM
L‑glutamine (Sigma‑Aldrich; Merck KGaA, Darmstadt,
Germany), 2 ng/ml human basic fibroblast growth factor and
10 ng/ml human epidermal growth factor (PeproTech, Inc.,
Rocky Hill, NJ, USA). Platelet‑derived growth factor‑BB
(PDGF‑BB) was also purchased from PeproTech, Inc.
Following culture at 37˚C in a humid atmosphere with 5% CO2
for 3 days, the culture medium was completely replaced and
non‑adherent cells were removed. When the cells had reached
~80‑85% confluence, the adherent cells were detached by treatment with 0.125% trypsin and 0.1% EDTA (Sigma‑Aldrich;
Merck KGaA), and put back into the medium at a 1:2 dilution
under the same culture conditions.

At passage 3, adherent cells were identified by surface
markers with monoclonal antibodies cluster of differentiation
(CD)29, CD166, CD44, CD73, CD34 and CD90 (BioLegend,
Inc., San Diego, CA, USA), CD45 (BD Pharmingen; Becton,
Dickinson and Company, Franklin Lakes, NJ, USA), CD105
(Abcam, Cambridge, MA, USA) using a FACS flow cytometer
(BD Biosciences, Becton, Dickinson and Company; the details
of all the antibodies are described in Table I).
Morphology of BM‑MSCs. BM‑MSCs were cultured in
DMEM/F‑12 medium and observed under an inverted light
microscope. At the same time, BM‑MSCs were stained for
β‑tubulin for the morphology examination. BM‑MSCs were
grown on glass chamber slides at 90% confluence and fixed
with 4% paraformaldehyde at room temperature for 30 min.
Subsequently, the BM‑MSCs were first permeated with
cold acetone for 10 min and washed with ice‑cold PBS. The
BM‑MSCs were then blocked with 5% bovine serum albumin
(BSA; Sigma‑Aldrich, Merck KGaA) in PBS at room temperature for 30 min, followed by incubation with rabbit antihuman
β‑tubulin antibody (Thermo Fisher Scientific, Inc.) overnight
at 4˚C. After three washes with ice‑cold PBS, the BM‑MSCs
were incubated with goat tetramethylrhodamine‑conjugated
goat anti‑rabbit immunoglobulin G secondary antibody
(Thermo Fisher Scientific, Inc.; details of the antibodies are
described in the Table II) at room temperature for 30 min and
their nuclei were stained with 1 µg/µl 4',6‑diamidino‑2‑phenylindole (DAPI) at room temperature for 10 min. The cells
were then washed twice with ice‑cold PBS and the images
were visualized using a fluorescence microscope (Nikon
Corporation, Tokyo, Japan).
Cell proliferation assay. To assess the proliferation state
of the BM‑MSCs cells following the various treatments an
MTT (Sigma‑Aldrich; Merck KGaA) proliferation assay was
performed according to the manufacturer's protocol. In brief,
BM‑MSCs cells were seeded into 96‑well plates at a density of
2x104 cells/ml for 1‑4 days. An aliquot of 20 µl MTT labeling
reagent (5 mg/ml) was added daily to each well and the plates
were incubated at 37˚C for 4 h. The resulting formazan crystals
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Table II. Antibody information for fluorescence activated cell sorting.
Name

Clone ID

APC anti‑human CD29 antibody
TS2/16
		
PE anti‑human CD34 antibody
561
		
FITC anti‑human CD44 antibody
BJ18
		
PE anti‑human CD166 antibody
3A6
		
PerCP/Cyanine 5.5 anti‑human CD73
AD2
		
FITC anti‑human CD90 antibody
5.00E+10
		
PerCP/Cyanine 5.5 anti‑human
MEM‑229
CD105 antibody
APC anti‑human CD45 antibody
HI30
		

Manufacturer; cat. no.; RRID

Dilution

BioLegend, Inc. 303007, RRID:AB_314323;
mouse; monoclonal antibody
BioLegend, Inc.; 343605; RRID:AB_1732033;
mouse; monoclonal antibody
BioLegend, Inc.; 338803; RRID:AB_1501204;
mouse; monoclonal antibody
BioLegend, Inc.; 343903; RRID:AB_2289303;
mouse; monoclonal antibody
BioLegend, Inc.; 344013; RRID:AB_2561756;
mouse; monoclonal antibody
BioLegend, Inc.; 328107; RRID:AB_893438;
mouse; monoclonal antibody
Abcam; ab234265; mouse; monoclonal antibody

5 µl per million
cells in 100 µl
staining volume

BD Biosciences; 560973; RRID:AB_10565969;
mouse; monoclonal antibody

CD, cluster of differentiation; FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin.

were solubilized by adding 100 µl DMSO per well and the plates
were incubated at room temperature for 10 min. The absorbance
of formazan was measured at 575 nm and this was taken as the
measure for the proliferation state of the cells. Trypan blue cell
exclusion was also used at room temperature for 5 min to assess
cell viability and the cell number with a light microscope.
Apoptosis of BM‑MSCs. The apoptotic rate of the BM‑MSCs
was evaluated using a commercial fluorescein thiocyanate
(FITC)‑Annexin V apoptosis detection kit (Nanjing KeyGen
Biotech Co., Ltd., Nanjing, China), as recommended by the
manufacturer. BM‑MSCs (5x105 cells) were harvested, washed
and incubated in the Annexin V binding buffer. Subsequently,
the BM‑MSCs were stained with Annexin V‑FITC and
propidium iodide (PI), and flow cytometric analysis was then
performed using a flow cytometer (BD FACSAria™ III) and
the data were analyzed with FlowJo 7.6 software (FlowJo
LLC, Ashland, OR, USA). Apoptotic cells were identified in
the early (FITC‑Annexin V positive, PI negative) and the late
(FITC‑Annexin V and PI double‑positive) stages.
Reverse transcription‑quantitative polymerase chain reaction
(RT‑qPCR). TRIzol® reagent (Invitrogen; Thermo Fisher
Scientific, Inc.) was used to isolate total RNA, following the
manufacturer's protocol and the concentration of total RNA
was measured using a spectrophotometer following treatment
with DNase I (Invitrogen; Thermo Fisher Scientific, Inc.). A
sample (2 µg) of RNA was used for reverse transcription in
a 20 µl reaction containing EasyScript® reverse transcriptase
kit (TransGen Biotech Co., Ltd., Beijing, China.). The thermal
program consisted of 42˚C for 30 min, and then 85˚C for
5 sec to inactivate enzymes. RT‑qPCR was performed using
a Bio‑Rad RT‑PCR system instrument (Bio‑Rad Laboratories,
Inc., Hercules, CA, USA) with an SYBR®-Green PCR kit

(Roche Diagnostics, Indianapolis, IN, USA). Genes involved
in the cell cycle, proliferation and cell apoptosis were selected
for investigation. Details of all the primers are described
in Table III. The thermal cycling program consisted of 95˚C
for 10 min, followed by 40 cycles of 15 sec at 95˚C and 60 sec
at 60˚C. Relative quantities of target genes were determined
for unknown samples using the comparative threshold cycle
(ΔΔCq) method (16) and normalized against GAPDH as the
control. Each test sample was amplified in three different
wells with a 20 µl reaction volume, following the manufacturer's protocol for each specific experiment and each test was
repeated at least in triplicate.
Differentiation capacity of BM‑MSCs. BM‑MSCs were
induced to differentiate into osteoblasts and adipocytes using
the following procedure. The induction medium for osteogenesis was Gibco® Iscove's modified Dulbecco's medium (IMDM;
Thermo Fisher Scientific, Inc.) supplemented with 10% FBS,
0.1 µM dexamethasone, 0.2 mM ascorbic acid 2‑phosphate
and 10 mM glycerol 2‑phosphate (Sigma‑Aldrich; Merck
KGaA). The induction medium for adipogenesis was IMDM
supplemented with 10% FBS, 1 µM dexamethasone, 0.5 mM
3‑isobutyl‑1‑methylxanthine, 10 µg/ml insulin and 60 µM
indomethacin (Sigma‑Aldrich; Merck KGaA). After 3 days, the
culture medium was completely replaced and the medium was
subsequently changed twice weekly thereafter. After the predetermined culture time had elapsed, adipocytes were stained
with Oil Red O at room temperature for 30 min; the osteoblasts
were identified using alkaline phosphatase (ALP) and Alizarin
Red S assays were performed at room temperature in the dark
for 50 min (Sigma‑Aldrich; Merck KGaA).
Western blot analysis. The total proteins of the BM‑MSCs
were extracted with Pierce™ IP Lysis buffer (Thermo Fisher

Immunogen

Manufacturer; cat. no.; RRID; species
Abcam; ab32498; RRID:AB_731777;
rabbit; monoclonal antibody
Abcam; ab16123; RRID:AB_302274; mouse;
monoclonal antibody
Santa Cruz Biotechnology, Inc.; sc‑27156;
RRID:AB_2227600; goat; polyclonal antibody
Santa Cruz Biotechnology, Inc.; sc‑56021;
RRID:AB_781603; mouse; monoclonal antibody
Santa Cruz Biotechnology, Inc.; sc‑74540; RRID:
AB_1121387; mouse; monoclonal antibody
Cell Signaling Technology, Inc.; 3700, RRID:
AB_2242334; mouse; monoclonal antibody
Thermo Fisher Scientific, Inc.; PA5‑16863,
RRID:AB_10986058; rabbit; polyclonal antibody
Thermo Fisher Scientific, Inc.; A16101, RRID:AB_2534775;
goat; polyclonal antibody

AREG, amphiregulin; CCNA2; cyclin A2: CDKN2, cyclin‑dependent kinase inhibitor 2A; Ig, immunoglobulin.

Synthetic peptide within Human cyclin
A2 aa 100‑200 (N‑terminal)
CDKN2A
Recombinant full‑length protein corresponding
to Human CDKN2A/p16INK4a aa 1‑156
AREG
A peptide mapping near the N‑terminus
of amphiregulin of human origin
Bcl‑xl
Full length Bcl‑xL of human origin
		
Fas
Amino acids 1‑335 representing full
length FAS of human origin
β‑actin
A synthetic peptide corresponding to
amino‑terminal residues of human β‑actin
Β‑tubulin polyclonal antibody
‑
		
Goat anti‑rabbit IgG, TRITC
‑
		

CCNA2

Name

Table III. Antibody information for western blotting and immunofluorescence.

1:100

1:100

1:2,000

1:500

1:500

1:500

1:100

1:1,000

Dilution
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Scientific, Inc.) and the concentration was determined with
bicinchoninic acid (BCA) methods with a BCA protein assay
kit (Beijing Solarbio Science & Technology Co., Lt., Beijing,
China). The proteins were separated using 10% SDS‑PAGE
and 15 µg protein were loaded in each lane. Subsequently, the
proteins were transferred electrophoretically to a polyvinylidene difluoride membranes (Merck KGaA). The membranes
were blocked with 5% defatted milk at room temperature
for 1 h and then incubated with the primary antibodies overnight. The next day, the membranes were incubated with the
HRP‑conjugated secondary antibodies for 1 h. Protein bands
were detected using an Amersham ECL Western blotting detection kit (GE Healthcare Life Sciences, Little Chalfont, UK).
The protein bands were statistically analyzed with ImageJ 1.4
software (National Institutes of Health, Bethesda, MD, USA).
For western blotting analysis, the β‑actin antibody (used as the
loading control) was purchased from Santa Cruz Biotechnology,
Inc., (Dallas, TX, USA); the antibodies against cyclin A2
(CCNA2), cyclin‑dependent kinase inhibitor 2A (CDKN2A),
amphiregulin (AREG) and Bcl‑xl were from Cell Signaling
Technology, Inc., (Danvers, MA, USA); and the anti‑Fas antibody came from R&D Systems, Inc., (Minneapolis, MN, USA).
All antibodies are described in further detail in Table II.
Statistical analysis. Each experiment was repeated at least
three times. All data are presented as the mean ± standard
deviation. The difference between means was statistically
analyzed using a t‑test. All statistical analyses were performed
using GraphPad Prism 6 software (GraphPad Software, Inc.,
La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
NMO patient‑derived BM‑MSCs exhibit normal differentiation
capacity and a similar morphology compared with BM‑MSCs
derived from healthy controls. Aliquots of 5‑10 ml adult donor
bone marrow aspirates (five from patients with NMO and five
from age‑ and sex‑matched healthy subjects) were provided by
the Department of Hematology of Tianjin Medical University
General Hospital. After isolation, BM‑MSCs at passage 3
were harvested to analyze their immunophenotype using flow
cytometric analysis. BM‑MSCs from patients with NMO and
healthy controls were revealed to express CD105, CD73, CD90,
CD29, CD44 and CD166, although they lacked expression
of CD34 and CD45 (Table IV). All the BM‑MSCs formed a
monolayer of bipolar spindle‑like cells, with a ‘whirlpool‑like’
array. However, certain BM‑MSCs from the patients with
NMO were observed to be aberrant, with an irregular and
ragged appearance following staining with β‑tubulin under a
fluorescence confocal microscope. Compared with the elongated morphology of the BM‑MSCs from the healthy controls,
certain BM‑MSCs from patients with NMO also exhibited a
‘cobblestone'‑like’ appearance (Fig. 1A).
The differentiation capabilities of BM‑MSCs were subsequently investigated following induction with the differently
conditioned media. BM‑MSCs were able to differentiate into
osteoblasts and adipocytes, as tested by positive staining of
ALP and Alizarin Red S (for osteoblasts), and Oil Red O (for
adipocytes). The results revealed that the BM‑MSCs from
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the healthy controls and the patients with NMO were easily
induced to differentiate into osteoblasts and the adipocyte
lineage (Fig. 1B). There appeared to be no obvious differences
in the differentiation capability between BM‑MSCs from
either the healthy controls or the patients with NMO. These
data indicated that there was little discrepancy in morphology
between BM‑MSCs from healthy control subjects and the
patients with NMO, since all the BM‑MSCs had very similar
differentiation capabilities.
NMO patient‑derived BM‑MSCs exhibit decreased prolif‑
erative capability in vitro. The proliferative capability of
the BM‑MSCs was measured using a non‑radioactive MTT
assay method. The extent of cell proliferation was measured
following culture for 0, 1, 2, 3 and 4 days, in a regular MSC
culture medium. As presented in Fig. 2A, the proliferation
rate of BM‑MSCs from the patients with NMO was decreased
compared with the healthy controls from day 3. However,
following 4 days of culture, the proliferation of the BM‑MSCs
from the patients with NMO was significantly decreased
(P<0.05). In addition, along with the proliferation assay, the
mRNA expression levels of an array of cell cycle‑ and proliferation‑associated genes in the BM‑MSCs from the patients
with NMO and healthy controls were detected by RT‑qPCR
(Fig. 2B and C). These experiments revealed that the expression levels of AREG and CCNA2 were significantly decreased
in BM‑MSCs from the patients with NMO compared with the
healthy controls (P<0.05), whereas the expression of CDKN2A
significantly increased in the patient group (P<0.05). Changes
in the protein levels of the above genes revealed a similar
tendency. Three experimental subjects were randomly selected
from the NMO patient group and the healthy subject group,
respectively, and these exhibited the same tendency (Fig. 3A
and B). These data suggested that the proliferative capabilities of BM‑MSCs from the patients with NMO were lower
compared with those of BM‑MSCs from the healthy controls.
NMO patient‑derived BM‑MSCs exhibit increased senes‑
cence in vitro. The viability of BM‑MSCs was subsequently
compared between the patients with NMO and the healthy
controls, as indicated by the apoptotic rate of BM‑MSCs
under normal culture conditions. As presented in Fig. 4, the
apoptotic rate of BM‑MSCs from the patients with NMO
was three times higher compared with the healthy controls.
In addition, the expression levels of an array of cell apoptosis
and cell death‑associated genes were compared between the
two groups. Of the genes assessed, the expression of Fas was
revealed to be significantly increased (P<0.05), whereas that
of the pro‑survival gene Bcl‑xl was significantly decreased in
BM‑MSCs from the patients with NMO at the mRNA and the
protein levels (P<0.01; Fig. 4B‑D). These data suggested that
senescence may be increased in the BM‑MSCs from patients
with NMO compared with the healthy controls. Furthermore,
the BM‑MSCs from patients with NMO were at a disadvantage
in terms of their self‑renewal capability.
PDGF‑BB can stimulate cell proliferation and overcome
the senescence disadvantage, of BM‑MSCs from patients
with NMO. Several growth factors and cytokines have been
considered to be critical factors regulating MSC proliferation,
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Table IV. Quantitative‑polymerase chain reaction primer
sequences.
Genes
AIF
ATM
BAX
Bcl‑xl
Caspase 3
Caspase 8
CYCS
FADD
Fas
FasL
TNFSF10
TRADD
CCNA2
CCNB1
CCNE2
CDC2
CDC20
CDK4
CDK6
CDKN2A
ORC5L
SMAD3
YWHAZ
AREG
CXCL1

Sequence (5'‑3')
F: ATCTACAGGTGCTTCTGG
R: GGCCTTTTTCTGTTTCTG
F: GTGCCAGAATGATAAAGC
R: GAAGCCAATACTGGACTG
F: GACGGCAACTTCAACTGG
R: GGAGGAAGTCCAATGTCC
F: GCTGGTGGTTGACTTTCT
R: TCCATCTCCGATTCAGTC
F: TCTGGAATATCCCTGGAC
R: ATGTTTCCCTGAGGTTTG
F: CCTGAGCCTGGACTACAT
R: TCAGGAAGGACAGATTGC
F: GCCCCTGGATACTCTTAC
R: GCCCTTTCTTCCTTCTTC
F: GGTGTCGTCCAGCCTGTC
R: TCCAGGTCGTTCTGCTCC
F: GATGACCGTCGCTGGAAG
R: CCATCGTGTGTGCCTGCT
F: CTCCAGGCACAGTTCTTC
R: GTGGTTCCCTCTCTTCTT
F: ATGGCTATGATGGAGGTC
R: AGAAACAAGCAATGCCAC
F: CAAAATGGGCACGAAGAG
R: CGGTGGATCTTCAGCATC
F: ACAGTAAACAGCCTGCGTTC
R: CAGGGCATCTTCACGCTCTA
F: GTGCCAGTGCCAGTGTCTGA
R: CCATTGGGCTTGGAGAGGCA
F: TGTAACAATCATCTCCTGGC
R: GGAGGTAAAATGGCACAAGG
F: TAGAAAGTGAAGAGGAAGGG
R: TACTGACCAGGAGGGATAGA
F: CAAAGCCAAGGAAGCCGCAG
R: TCACCGCCAGGTTTGCTAGG
F: CGGTGCCTATGGGACAGTGT
R: CAGTCGCCTCAGTAAAGCCA
F: TGCTGAGGCACCTGGAGACC
R: TCAGTGGGCACTCCAGGCTC
F: TTCCTGGACACGCTGGTGGT
R: GGTTACTGCCTCTGGTGCCC
F: ATACTGGATGCTTTGAGCCG
R: TAGGCAGCATAGAAATCAGC
F: GCGGTCAAGAGCCTGGTCAA
R: CACAGGCGGCAGTAGATGAC
F: ATGTTGTAGGAGCCCGTAGG
R: TTTGCTCTCTGCTTGTGAAG
F: GGTGCTGTCGCTCTTGAT
R: GCATTTCACTCACAGGGG
F: CCCAAACCGAAGTCATAG
R: CCTTCTGGTCAGTTGGAT

Table IV. Continued
Genes
DLG7
DLGAP5
KITLG

Sequence (5'‑3')
F: ACCTGGTCCAAGACAAAC
R: CTGCTTTGCTGCTTGAGT
F: CTACTCAAGCAGCAAAGC
R: GGCAGGTCTTCCTTTACT
F: GTCATTGTTGGATAAGCG
R: TCTGGGCTCTTGAATGAT

Figure 1. Representative morphological and differentiation images of
BM‑MSCs derived from patients with NMO and healthy controls. (A) The
morphology of BM‑MSCs is presented following staining with β ‑tubulin
(red coloration). The nuclei of BM‑MSCs were stained with DAPI (indicated
by the blue staining). The arrows indicate the ‘cobblestone‑like’ appearance
of BM‑MSCs from the patients with NMO. (B) The osteogenic differentiation capacity of BM‑MSCs was detected by positive staining of ALP (upper
panel) and Alizarin Red (middle panel). The adipogenic differentiation
capacity of BM‑MSCs was detected by positive staining of Oil Red O (lower
panel). BM‑MSC, bone marrow‑derived mesenchymal stem cell; NMO,
neuromyelitis optica; DAPI, 4',6‑diamidino‑2‑phenylindole; ALP, alkaline
phosphatase.
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Figure 2. Expression patterns of proliferation and cell cycle‑associated genes of BM‑MSCs derived from patients with NMO and healthy controls.
(A) Proliferation rate of the BM‑MSCs was detected using an MTT assay at the culture time points indicated. (B) The cell proliferation‑associated gene profile
was determined using RT‑qPCR. (C) The cell cycle‑associated gene profile was determined using RT‑qPCR. *P<0.05 vs. the healthy control. BM‑MSC, bone
marrow‑derived mesenchymal stem cell; NMO, neuromyelitis optica; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction.

migration and differentiation, among which PDGF is regarded
as the most potent mitotic stimulatory factor (17,18). PDGFs
are disulfide‑linked homodimers or heterodimers, consisting
of several 12.0‑13.5 kDa polypeptide chains designated as the
PDGF‑A, ‑B, ‑C and ‑D chains and the five naturally occurring PDGFs are PDGF‑AA, PDGF‑BB, PDGF‑AB, PDGF‑CC
and PDGF‑DD (18). Considering that PDGF‑BB is the major
growth factor in bone matrix and its safety and effectiveness
have been verified in a number of clinical trials (19,20), it
seemed logical during these experiments to supplement the
NMO BM‑MSC culture medium with PDGF‑BB in order
to optimize the BM‑MSCs' biological properties. The MTT
assay experiment revealed that 20 ng/ml PDGF‑BB was able
to significantly promote the proliferation rate of BM‑MSCs
from patients with NMO on days 3 and 4 (P<0.05; Fig. 5A).
Furthermore, the cytometric images indicated that the apoptotic rate of the NMO patient group was decreased from
9.745±0.245% to 3.672±0.128% (P<0.01; Fig. 5B). Additionally,
improvements at the molecular level were also confirmed
by RT‑qPCR. As presented in Fig. 5C, the expression levels
of AREG, CCNA2 and Bcl‑xl were significantly increased
(P<0.01); conversely, the expression levels of CDKN2A and
Fas were significantly decreased (all P<0.05). The protein
expression levels following PDGF‑BB treatment in MSC cells
from the identical patients were also examined. Three patients
were selected and the protein expression levels of AREG,
CCNA2 and Bcl‑xl were revealed to be significantly increased
in the patients with NMO MSC with PDGF (P<0.05), whereas

Figure 3. Different protein expression patterns of BM‑MSCs from patients
with NMO and healthy controls. (A) Representative results of the protein
expression patterns of AREG, CCNA2 and CDKN2A, as determined by
western blot analysis, are presented. Samples #1, #2 and #3 were taken from
the healthy volunteers, whereas samples #5, #6, #7 were from the NMO patient
group. (B) The relative protein expression levels of AREG, CCNA2 and
CDKN2A. For the western blot analysis, the protein bands were statistically
analyzed with ImageJ software and β‑actin was used as an internal control.
Results are presented as the mean ± standard deviation of three independent experiments and each experiment was performed in triplicate. **P<0.01
and ***P<0.001 vs. the healthy control. BM‑MSC, bone marrow‑derived
mesenchymal stem cell; NMO, neuromyelitis optica; AREG, amphiregulin;
CCNA2, cyclin A2; CDKN2, cyclin‑dependent kinase inhibitor 2A.
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Figure 4. The apoptotic rate and apoptosis‑associated gene expression patterns of BM‑MSCs from patients with NMO and healthy controls. (A) Representative
dot plots of the apoptotic rate of BM‑MSCs are presented. (B) The global apoptosis‑associated gene expression profile of BM‑MSCs was determined using
RT‑qPCR. (C) The protein expression levels of Bcl‑xl and Fas were determined by western blotting and representative results are presented. Samples #1, #2
and #3 were taken from the healthy volunteers, whereas samples #5, #6, #7 were from the NMO patient group. (D) Relative protein expression levels of Bcl‑xl
and Fas. For the western blot analysis, the protein bands were statistically analyzed with ImageJ software and β‑actin was used as an internal control. Results
are presented as the mean ± standard deviation of three independent experiments and each experiment was performed in triplicate. *P<0.05 and **P<0.01
vs. the healthy controls. BM‑MSC, bone marrow‑derived mesenchymal stem cell; NMO, neuromyelitis optica; RT‑qPCR, reverse transcription‑quantitative
polymerase chain reaction; FITC, fluorescein isothiocyanate; PI, propidium iodide.

the expression levels of Fas and CDKN2A were significantly
decreased (P<0.01; Fig. 6A and B).
Discussion
NMO is a humoral immunity‑mediated inflammatory demyelinating disease that preferentially targets the spinal cord and optic
nerves (21). NMO is associated with a generally poor prognosis
and the permanent myelin losses that precede and characterize
the progressive stage of NMO remain untreatable (22). Stem cell
transplantation has been considered to be a potential treatment
method for neurological disorders due to the multifaceted roles
of stem cells. Greco et al (23) applied hematopoietic stem cells
to treat NMO and discovered that the treatment was able to
reduce neuroinflammation and halt the progression of disability.
By contrast, Matiello et al (24) demonstrated that autologous
hematopoietic stem cell transplantation was unable to prevent
the relapse of NMO (24). These results provide the foresight that
caution is necessary in terms of selecting an appropriate type of
stem cells to treat NMO.
MSCs have been extensively studied as cellular therapies due to their various modes of action. MSCs exhibit

numerous characteristics, including immune modulatory,
neurotrophic (25) and repair‑promoting properties, which
make them attractive candidates for treating various degenerative neurological diseases, including stroke (26,27), multiple
sclerosis (13,28) and Parkinson's disease (29,30). In 2012,
Lu et al (31) reported that four out of five patients with NMO
demonstrated therapeutic improvements following receiving
human umbilical cord MSC therapy (31). However, the use
of these allogeneic cells is associated with ethical concerns
and the possibility of immunological rejection. Although the
authors' recent clinical pilot observation revealed that the
infusion of autologous MSCs provided beneficial effects in
terms of lowering the relapse rate and disability in patients
with NMO (15), further studies are required in order to focus
on the cytological features of patient‑derived BM‑MSCs that
may influence the therapeutic effects on patients with NMO.
Therefore, the present study aimed to demonstrate whether the
biological properties of BM‑MSCs from patients with NMO
are different from those of BM‑MSCs taken from healthy
control subjects. The results obtained revealed that there was
no difference in the immune phenotype markers of BM‑MSCs,
comparing between the patients with NMO and healthy
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Figure 5. PDGF‑BB can stimulate proliferation and overcome the senescence disadvantage, of BM‑MSCs from patients with NMO. (A) The proliferation curve of
BM‑MSCs from patients with NMO treated with PDGF‑BB (20 ng/ml) is presented. (B) Representative dot plots demonstrating the apoptotic rate of BM‑MSCs
from patients with NMO treated with PDGF‑BB (20 ng/ml). (C) mRNA levels of AREG, CCNA2, CDKN2A and Fas genes in BM‑MSCs from patients with
NMO treated with PDGF‑BB (20 ng/ml), as determined using RT‑qPCR are presented. *P<0.05 and **P<0.01 vs. the controls. BM‑MSC, bone marrow‑derived
mesenchymal stem cell; NMO, neuromyelitis optica; RT‑qPCR, reverse transcription‑quantitative polymerase chain reaction; AREG, amphiregulin; CCNA2,
cyclin A2; CDKN2, cyclin‑dependent kinase inhibitor 2A; PGDF‑BB, platelet‑derived growth factor‑BB; FITC, fluorescein isothiocyanate; PI, propidium iodide.

controls. The appearances of certain of the BM‑MSCs from
the patients with NMO were revealed to be slightly aberrant,
even though they exhibited a normal differentiation capability;
however, the BM‑MSCs from patients did reveal decreased
proliferative capacity and increased senescence.
In addition to the observed biological phenomena, it
was determined that an array of cell cycle, proliferation and
apoptosis‑associated gene expression profiles varied between
the BM‑MSCs derived from the patients with NMO and the
healthy controls. Decreased expression levels of AREG have
been demonstrated to induce abnormalities of homeostasis
and to decrease cell proliferation (32). In addition, CDKN2A is
a gene that can induce arrested cell growth. The activation of
CDKN2A may inhibit the cell cycle transition from G1 to the S
phase by inhibiting cyclin‑dependent kinases (CDKs). CCNA2
belongs to the cyclin family that regulates the S phase of cell
cycle progression by interacting with CDKs and decreased
CCNA2 may arrest the cell cycle at S phase. Therefore, aberrant
expression of CKDN2A and CCNA2 may lead to maladjusted
cell growth. In the present study, the expression levels of Fas
in the patients with NMO were increased compared with those
of healthy controls. The Fas receptor is a death receptor on
the surface of cells that initiates programmed cell death when
bound to its ligand, Fas‑L and an increasing number of reports

have demonstrated that Fas overexpression is associated with
apoptosis and cell senescence (33‑35). Bcl‑xL is a canonical
anti‑apoptotic protein in the Bcl‑2 family. Bcl‑xL inhibits Bak
or Bax activation, which is an essential event for apoptosis and
senescence execution (36,37).
PDGF signaling pathways have long been demonstrated
to be involved in pre‑ and post‑natal vasculogenesis and/or
angiogenesis. PDGFs are potent mitogens for MSCs and are
involved in their growth and differentiation. PDGF isoforms
exert their biological effects via the activation of two tyrosine
kinase receptors, PDGF receptor‑α (PDGFR)‑α and PDGFR‑β,
which are abundantly expressed on MSCs (17). Studies have
been published on a large number of successful applications
of PDGF‑BB‑based therapies for various types of maladies,
including tendon and bone fracture repairs, and demyelinating disease (20,38). For example, Chen et al (19) performed
PDGF‑BB‑based stem cell gene therapy to improve bone
strength in hematopoietic stem cell transplantation subjects
and in their in vivo model the proliferation of BM‑MSCs
increased significantly compared with the control group (19).
In order to find the potential mechanism of different cytological features of BM MSCs from patients with NMO and
healthy subjects, 28 genes involved in the cell cycle, proliferation and cell apoptosis were screened with the RT‑qPCR
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features of BM‑MSCs from patients with NMO. Moreover,
the synergetic effects from two different proteins on the same
cell signaling pathway may serve critical roles in that progress.
However, whether there is a regulatory network or interaction
between these proteins needs to be further investigated.
In conclusion, it has been demonstrated in the present
study that, although the BM‑MSCs from patients with NMO
exhibited a similar cell morphology and differentiation ability
when compared with the healthy controls, the cells grew
more slowly and tended to be a little more inclined towards
senescence. These aberrant changes in cytological features
of patient‑derived BM‑MSCs could influence the therapeutic
effects of autologous BM‑MSC infusion treatment in NMO.
Promising approaches to overcome the above‑mentioned
defects were to routinely add PDGF in vitro during the expansion phase of the BM‑MSCs, or to combine PDGF cytokine
therapy with BM‑MSC infusion in refractory patients with
NMO. Although the present study has provided a theoretical
basis for treatment of NMO, further studies are required in
view of the limited number of patients with NMO. In addition, the immune modulatory and neurotrophic effects of these
cells that were not included in this study also require further
investigation.
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